出典:Wikipedia
出典:『Wikipedia』 (2011/05/23 07:41 UTC 版)
Afatinib (INN; planned trade name Tomtovok, previously Tovok) is a candidate drug against non-small cell lung carcinoma, developed by Boehringer Ingelheim. As of December 2008, it is undergoing a Phase III clinical trial for this indication, and Phase II trials for breast, prostate, and head and neck cancers, as well as glioma.